Levosulpirida Stada

Levosulpiride, the active ingredient in Levosulpirida Stada, is a benzamide derivative presented as an oral formulation for oral use. It treats schizophrenia, depressive disorders, functional dyspepsia and gastroesophageal reflux disease in adult patients.

GNH USA supplies Levosulpirida Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies, clinics and research institutions worldwide.

Levosulpiride is used in psychiatric and gastrointestinal disorders that involve dopamine dysregulation.

- Schizophrenia: alleviates positive and negative symptoms in adult patients. - Depressive disorders: augments antidepressant response and improves mood. - Functional dyspepsia: enhances gastric motility and reduces dyspeptic discomfort. - Gastroesophageal reflux disease: increases lower esophageal sphincter tone and decreases reflux episodes.

Levosulpiride may cause a range of adverse reactions, varying in frequency and severity.

Common Side Effects: - Nausea - Headache - Dizziness - Dry mouth

Serious or Rare Side Effects: - Extrapyramidal symptoms such as akathisia or dystonia - Neuroleptic malignant syndrome - Severe allergic reactions, including anaphylaxis

Use of levosulpiride requires careful consideration of several safety aspects.

- Pregnancy: safety not established; avoid unless clearly needed. - Breastfeeding: unknown excretion; consider risk versus benefit. - Renal impairment: dose adjustment may be required. - Hepatic impairment: use with caution and monitor liver function. - Elderly patients: increased sensitivity to central effects; start at low dose. - Store at room temperature: keep in original packaging, protect from moisture and light.

Levosulpiride can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Strong D2 antagonists (e.g., haloperidol): heightened risk of extrapyramidal effects. - Monoamine oxidase inhibitors: potential for hypertensive crisis. - QT‑prolonging agents (e.g., quinidine): additive cardiac risk.

Moderate Interactions (Monitor Closely): - CYP2D6 inhibitors (e.g., fluoxetine): may increase levosulpiride plasma levels. - Central nervous system depressants (e.g., benzodiazepines): enhanced sedation.